Details for Patent: 12,433,914

Which drugs does patent 12,433,914 protect, and when does it expire?

Patent 12,433,914 protects SUFLAVE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 12,433,914

Title:	Methods of administering safe colon cleansing compositions
Abstract:	Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Inventor(s):	Edmund V. Dennett, Mark Cleveland, Russell W. Pelham, Matthew Walker
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US19/062,757
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,433,914

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	SUFLAVE	magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	215344-001	Jun 15, 2023		RX	Yes	Yes	12,433,914					GASTROINTESTINAL FLAVORED SOLUTION INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY

International Family Members for US Patent 12,433,914

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2024256873